Dr. Reddy's Laboratories Limited
RDY
$12.70
-$0.21-1.63%
| Weiss Ratings | RDY - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Fair | |||
| Risk Grade | C- | |||
| Reward Grade | B | |||
| Rating Factors | RDY - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | RDY - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.19 | |||
| Price History | RDY - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -1.93% | |||
| 30-Day Total Return | -9.35% | |||
| 60-Day Total Return | -12.23% | |||
| 90-Day Total Return | -16.86% | |||
| Year to Date Total Return | -18.95% | |||
| 1-Year Total Return | -16.67% | |||
| 2-Year Total Return | 18.34% | |||
| 3-Year Total Return | 28.09% | |||
| 5-Year Total Return | 62.56% | |||
| 52-Week High % Change | -23.57% | |||
| 52-Week Low % Change | 2.30% | |||
| Price | RDY - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $16.89 | |||
| 52-Week Low Price | $12.62 | |||
| 52-Week Low Price (Date) | Feb 28, 2025 | |||
| 52-Week High Price (Date) | Aug 09, 2024 | |||
| Valuation | RDY - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 10.83B | |||
| Enterprise Value | 10.78B | |||
| Price/Earnings (TTM) | 16.79 | |||
| Earnings Per Share (TTM) | 0.77 | |||
| Earnings Per Share Growth | 1.36% | |||
| Price/Earnings To Growth | 12.44 | |||
| Price/Sales (TTM) | 2.90 | |||
| Price/Book (Q) | 2.90 | |||
| Enterprise Value/Revenue (TTM) | 2.90 | |||
| Price | $12.70 | |||
| Enterprise Value/EBITDA (TTM) | 10.67 | |||
| Enterprise Value/EBIT | 12.98 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | RDY - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 834.30M | |||
| Dividend Yield | 0.63% | |||
| Div. Per Share (Most Recent) | $0.08 | |||
| Dividend Per Share (TTM) | $0.08 | |||
| Payout Ratio (TTM) | 12.40% | |||
| Dividend Per Share (Most Recent) | $0.08 | |||
| Company Info | RDY - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 91 40 4900 2900 | |||
| Address | -- | |||
| Website | www.drreddys.com | |||
| Country | India | |||
| Year Founded | 1984 | |||
| Profitability | RDY - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 22.31% | |||
| Profit Margin | 17.24% | |||
| Management Effectiveness | RDY - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 10.27% | |||
| Return on Equity | 18.65% | |||
| Income Statement | RDY - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 3.72B | |||
| Total Revenue (TTM) | 3.72B | |||
| Revenue Per Share | $4.46 | |||
| Gross Profit (TTM) | 2.21B | |||
| EBITDA (TTM) | 1.01B | |||
| EBIT (TTM) | 829.90M | |||
| Net Income (TTM) | 641.44M | |||
| Net Income Avl. to Common (TTM) | 641.44M | |||
| Total Revenue Growth (Q YOY) | 14.17% | |||
| Earnings Growth (Q YOY) | 0.33% | |||
| EPS Diluted (TTM) | 0.77 | |||
| EPS Diluted Growth (Q YOY) | 0.91% | |||
| Balance Sheet | RDY - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 700.19M | |||
| Cash Per Share (Q) | $0.84 | |||
| Total Current Assets (Q) | 2.96B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 3.76B | |||
| Current Ratio (Q) | 1.918 | |||
| Book Value Per Share (Q) | $4.46 | |||
| Total Assets (Q) | 5.62B | |||
| Total Current Liabilities (Q) | 1.54B | |||
| Total Debt (Q) | 596.93M | |||
| Total Liabilities (Q) | 1.86B | |||
| Total Common Equity (Q) | 3.71B | |||
| Cash Flow | RDY - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -671.70M | |||
| Cash from Financing (TTM) | 307.75M | |||
| Net Change in Cash (TTM) | 65.30M | |||
| Levered Free Cash Flow (TTM) | 134.37M | |||
| Cash from Operations (TTM) | 430.17M | |||
